N/A
Completed N=148
Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)
Source: ClinicalTrials.gov NCT00818272 ↗Enrolled (actual)
148
Serious AEs
0.0%
Results posted
Feb 2012
Primary outcomePrimary: Number of Participants Who Had the Mendel Mantoux Test as the First Screening Test for Active or Latent Tuberculosis (TB) Before Starting Treatment — 92; 53; 3 Participants
Summary
This observational study is in line with the German educational plan with the aim to implement a tool to increase and monitor the awareness for tuberculosis screening and to reinforce the patient eligibility for a treatment with Remicade according to the Summary of Product Characteristics (SmPc).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Had the Mendel Mantoux Test as the First Screening Test for Active or Latent Tuberculosis (TB) Before Starting Treatment |
92; 53; 3 | — |
| PRIMARY Number of Participants Who Had the Tine Test as the First Screening Test for Active or Latent Tuberculosis Before Starting Treatment |
40; 105; 3 | — |
| PRIMARY Number of Participants Who Had the In-vitro TB Test as the First Screening Test for Active or Latent Tuberculosis Before Starting Treatment |
0; 90; 58 | — |
| PRIMARY Number of Participants Who Had a Chest X-ray as Part of TB Screening for Active or Latent Tuberculosis Before Starting Treatment |
131; 14; 3 | — |
| SECONDARY Assessment of Disease Activity by Means of the Crohn's Disease Activity Index (CDAI) at the Time of Enrollment and at the First Infusion |
302.67; 323.21 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects with Crohn's disease.
Exclusion Criteria
- As per SmPC
Data sourced from ClinicalTrials.gov (NCT00818272). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.